Nanoparticle-Mediated Targeting of Cyclosporine A Enhances Cardioprotection Against Ischemia-Reperfusion Injury Through Inhibition of Mitochondrial Permeability Transition Pore Opening

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Ikeda, Gentaro ^a   Matoba, Tetsuya ^a   Nakano, Yasuhiro ^a   Nagaoka, Kazuhiro ^a   Ishikita, Ayako ^a   Nakano, Kaku ^a,b   Funamoto, Daiki ^b   Sunagawa, Kenji ^a   Egashira, Kensuke ^a,b  

^a Department of Cardiovascular Medicine ^*  (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTONIC AGENT; CARRIER PROTEIN; CYCLOSPORIN; CYTOCHROME C; DRUG CARRIER; HYDROGEN PEROXIDE; LACTIC ACID; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; PROTEIN BAX;

ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; CELL CULTURE; CHEMISTRY; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; HEART MITOCHONDRION; HEART VENTRICLE REMODELING; MALE; METABOLISM; MOUSE; MYOCARDIAL REPERFUSION INJURY; OXIDATIVE STRESS; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CARDIOTONIC AGENTS; CELLS, CULTURED; CYCLOSPORINE; CYTOCHROMES C; DISEASE MODELS, ANIMAL; DRUG CARRIERS; HYDROGEN PEROXIDE; LACTIC ACID; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA, HEART; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; NANOPARTICLES; OXIDATIVE STRESS; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR REMODELING;

EID: 84957585717     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20467     Document Type: Article

References (36)

1. Yellon, D. M. & Hausenloy, D. J. Myocardial reperfusion injury. N Engl J Med 357, 1121-1135, doi: 10.1056/NEJMra071667 (2007).
2. Downey, J. M. & Cohen, M. V. Why do we still not have cardioprotective drugs? Circ J 73, 1171-1177 (2009).
3. Miura, T. & Miki, T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol 103, 501-513, doi: 10.1007/s00395-008-0743-y (2008).
4. Nakagawa, T. et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434, 652-658, doi: 10.1038/nature03317 (2005).
5. Baines, C. P. et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434, 658-662, doi: 10.1038/nature03434 (2005).
6. Piot, C. et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359, 473-481, doi: 10.1056/NEJMoa071142 (2008).
7. Mewton, N. et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol 55, 1200-1205, doi: 10.1016/j.jacc.2009.10.052 (2010).
8. Cung, T. T. et al. Cyclosporine before PCI in Patients with Acute Myocardial Infarction. The N Engl J Med 373, 1021-1031, doi: 10.1056/NEJMoa1505489 (2015).
9. Kimura, S. et al. Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. Circulation 118, S65-70, doi: 10.1161/CIRCULATIONAHA.107.740613 (2008).
10. Kubo, M. et al. Therapeutic neovascularization by nanotechnology-mediated cell-selective delivery of pitavastatin into the vascular endothelium. Arterioscler Thromb Vasc Biol 29, 796-801, doi: 10.1161/ATVBAHA.108.182584 (2009).
11. Oda, S. et al. Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia. J Vasc Surg 52, 412-420, doi: 10.1016/j.jvs.2010.03.020 (2010).
12. Chen, L. et al. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension 57, 343-350, doi: 10.1161/HYPERTENSIONAHA.110.157032 (2011).
13. Tsukie, N. et al. Pitavastatin-incorporated nanoparticle-eluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model. J Atheroscler Thromb 20, 32-45 (2013).
14. Katsuki, S. et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation 129, 896-906, doi: 10.1161/CIRCULATIONAHA.113.002870 (2014).
15. Ohtani, K. et al. Stent-based local delivery of nuclear factor-kappaB decoy attenuates in-stent restenosis in hypercholesterolemic rabbits. Circulation 114, 2773-2779, doi: 10.1161/CIRCULATIONAHA.105.582254 (2006).
16. Dauber, I. M. et al. Functional coronary microvascular injury evident as increased permeability due to brief ischemia and reperfusion. Circ Res 66, 986-998 (1990).
17. Jin, B. Y., Lin, A. J., Golan, D. E. & Michel, T. MARCKS protein mediates hydrogen peroxide regulation of endothelial permeability. Proc Natl Acad Sci USA 109, 14864-14869, doi: 10.1073/pnas.1204974109 (2012).
18. Leuschner, F. et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29, 1005-1010, doi: 10.1038/nbt.1989 (2011).
19. Acharya, S. & Sahoo, S. K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 63, 170-183, doi: 10.1016/j.addr.2010.10.008 (2011).
20. Burger, D. et al. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 72, 51-59, doi: doi: 10.1016/j.cardiores.2006.06.026 (2006).
21. Oie, E., Bjornerheim, R., Clausen, O. P. & Attramadal, H. Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats. Am J Physiol Heart Circ Physiol 278, H2115-2123 (2000).
22. Zorov, D. B., Filburn, C. R., Klotz, L. O., Zweier, J. L. & Sollott, S. J. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med 192, 1001-1014 (2000).
23. Juhaszova, M. et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113, 1535-1549, doi: 10.1172/JCI19906 (2004).
24. Durazo, S. A. & Kompella, U. B. Functionalized nanosystems for targeted mitochondrial delivery. Mitochondrion 12, 190-201, doi: 10.1016/j.mito.2011.11.001 (2012).
25. Marrache, S. & Dhar, S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci USA 109, 16288-16293, doi: 10.1073/pnas.1210096109 (2012).
26. Vasir, J. K. & Labhasetwar, V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 59, 718-728, doi: 10.1016/j.addr.2007.06.003 (2007).
27. Nagahama, R. et al. Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia. Arterioscler Thromb Vasc Biol 32, 2427-2434, doi: 10.1161/ATVBAHA.112.253823 (2012).
28. Danhier, F. et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161, 505-522, doi: 10.1016/j.jconrel.2012.01.043 (2012).
29. Gateau-Roesch, O., Argaud, L. & Ovize, M. Mitochondrial permeability transition pore and postconditioning. Cardiovasc Res 70, 264-273, doi: 10.1016/j.cardiores.2006.02.024 (2006).
30. Lin, M. J. et al. Massive palmitoylation-dependent endocytosis during reoxygenation of anoxic cardiac muscle. eLife 2, e01295, doi: 10.7554/eLife.01295 (2013).
31. Pierre, S. V., Belliard, A. & Sottejeau, Y. Modulation of Na(+)-K(+)-ATPase cell surface abundance through structural determinants on the alpha1-subunit. Am J Physiol Cell Physiol 300, C42-48, doi: 10.1152/ajpcell.00386.2010 (2011).
32. Hsu, C. P. et al. Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation 122, 2170-2182, doi: 10.1161/CIRCULATIONAHA.110.958033 (2010).
33. Foster, D. B. et al. Mitochondrial ROMK Channel Is a Molecular Component of MitoK(ATP). Circ Res 111, 446-454, doi: Doi 10.1161/Circresaha.112.266445 (2012).
34. Tanaka, C., Kawai, R. & Rowland, M. Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues. Drug Metab Dispos 28, 582-589 (2000).
35. Fujino, T. et al. Recombinant mitochondrial transcription factor A protein inhibits nuclear factor of activated T cells signaling and attenuates pathological hypertrophy of cardiac myocytes. Mitochondrion 12, 449-458, doi: 10.1016/j.mito.2012.06.002 (2012).
36. Molica, F. et al. Cannabinoid receptor CB2 protects against balloon-induced neointima formation. Am J Physiol Heart Circ Physiol 302, H1064-1074, doi: 10.1152/ajpheart.00444.2011 (2012).